Related Experiment Video

Updated: Jun 8, 2026

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models
09:18

Multianimal Magnetic Resonance Imaging for Tumor Measurements in Pancreatic Cancer Mouse Models

Published on: February 3, 2026

New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors

Ben Lawrence1, Bjorn I Gustafsson, Mark Kidd

  • 1Department of Medical Oncology, Auckland City Hospital, Private Bag 92024, Auckland, New Zealand.

Gastroenterology Clinics of North America
|October 19, 2010
PubMed

Insights

Systemic therapy is key for treating unresectable and metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Treatment choice varies by tumor type, with chemotherapy accepted for poorly differentiated GEP-NETs.

Area of Science:

  • Oncology
  • Medical Science

Background:

  • Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) present challenges in unresectable and metastatic stages.
  • Multidisciplinary approaches are essential for effective GEP-NET management.

Purpose of the Study:

  • To outline current systemic therapy options for GEP-NETs.
  • To contextualize these options within the latest World Health Organization (WHO) GEP-NET classification.

Main Methods:

  • Review of established and emerging systemic therapies for GEP-NETs.
  • Analysis of treatment efficacy based on tumor differentiation and molecular pathways.

Main Results:

  • Somatostatin analogues are effective for symptom management.
  • Interferon and radiopeptide therapies have unclear efficacy.
  • Tyrosine kinase and antiangiogenic agents show variable utility.
  • Cytotoxic chemotherapy is accepted for poorly differentiated GEP-NETs.

Conclusions:

  • Systemic therapy selection for GEP-NETs requires careful consideration of tumor pathology and classification.
  • The optimal treatment for indolent GEP-NETs remains uncertain.
  • Ongoing research is examining novel agents targeting angiogenesis and proliferation pathways.

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...